| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Haddadin Yezan Munther is a Director at OTLK. Recent filings cover 8 purchases and 0 sales. Those positions are worth an estimated $55K at current prices.
Our model assigns Haddadin Yezan Munther a below-average insider score of 29/100, based on 5 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -55.2%.
Haddadin Yezan Munther's largest disclosed position is in OTLK as Director, worth about $55K. Net of sales, the recent Form 4 record there shows accumulation of 128,225 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | OTLK Outlook Therapeutics, Inc. | Director | Buy | 29,000 | $0.83 | $24,145.40 | +78.0% | - | - | |
| May 26, 2026 | OTLK Outlook Therapeutics, Inc. | Director | Buy | 34,000 | $0.44 | $14,960.00 | +1,074% | - | - | |
| Mar 28, 2024 | OTLK Outlook Therapeutics, Inc. | Director | Buy | 1,882 | $11.82 | $22,241.83 | +59.4% | -40.1% | -88.9% | |
| Oct 7, 2022 | OTLK Outlook Therapeutics, Inc. | Director | Buy | 33,343 | $1.29 | $42,940.47 | +111.1% | -18.3% | -81.9% | |
| Dec 2, 2021 | OTLK Outlook Therapeutics, Inc. | Director | Buy | 10,000 | $1.39 | $13,900.00 | +50.0% | +23.2% | -21.7% | |
| Apr 19, 2021 | OTLK Outlook Therapeutics, Inc. | Director | Buy | 10,000 | $1.82 | $18,200.00 | +100.0% | +28.4% | -1.6% | |
| Sep 22, 2020 | OTLK Outlook Therapeutics, Inc. | Director | Buy | 10,000 | $0.72 | $7,245.00 | New | - | - |